In medicine, there’s no more important organ than the heart, the pump that circulates oxygen carrying blood throughout the body, keeping every cell alive. When circulation stops, so does life. The single biggest cause of death worldwide is heart disease, taking the lives of millions of people around the world annually, and affecting millions of patients in the U.S.
It’s no surprise that heart disease also represents a huge global market, representing billions of dollars annually. And one of the most important elements in dealing with it is the ability to detect and analyze the disease at its basic levels, so that treatment can be both timely and targeted. Unfortunately, heart disease is often diagnosed only when clear manifestations of the disease first appear.
FluoroPharma Medical, provider of advanced medical diagnostic imaging products designed for use with positron emission tomography (PET) technology, makes it possible for doctors to see what’s happening with the heart at the cellular level, giving them a superior set of diagnostic tools for identifying and analyzing various aspects of heart disease. FluoroPharma’s proprietary molecular imaging agents leverage PET technology, allowing the detection and imaging of the most subtle biological processes. It offers new hope for cardiovascular patients, and significant prospects for FluoroPharma as part of the $1.7 billion molecular imaging agents industry.
FluoroPharma currently offers three key products addressing the cardiovascular market:
• CardioPET is an F-18 labeled, modified fatty acid that provides insight into regions of metabolic insufficiency in myocardium. It can identify patients that will benefit from PCI or revascularization and guide intervention, or evaluate coronary artery disease (CAD) in patients that cannot go through stress tests.
• BFPET is a novel cardiovascular blood flow imaging agent that concentrates in healthy myocardial cells. It can be used for the detection of presumptive CAD in combination with stress testing, as well as for the improved detection of CAD related to multi-vessel disease.
• VasoPET is an F-18 labeled agent that accumulates in areas of inflammation, and can identify coronary artery plaque. It can be used for evaluating patients experiencing Acute Coronary Syndrome or a risk of stroke, or for evaluating therapy following an acute cardiac event or stroke.
For more information, see the company website at www.FluoroPharma.com
Let us hear your thoughts below:
